Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Rebol Lavra |
** = Publikationen gelistet in SCI/SSCI/Pubmed
2026
Originalarbeit (Zeitschrift)
** Habich, D; Horvath, A; Feldbacher, N; Rebol, L; Nepel, M; Madl, T; Habisch, HJ; Baumann-Durchschein, F; Fürst, S; Plank, J; Rainer, F; Spindelböck, W; Stauber, RE; Tatscher, E; Wagner, M; Zollner, G; Stadlbauer, V
An observational study on the effect of l-ornithine-l-aspartate (LOLA) on the gut microbiome in liver cirrhosis. A single center phase 4 study.
Clin Nutr. 2026; 56: 106522
Doi: 10.1016/j.clnu.2025.11.007
Web of Science
PubMed
FullText
FullText_MUG
** Woltsche, J; Pacher-Deutsch, C; Fürst, S; Gulden, L; Schwarzl, J; Feldbacher, N; Nepel, M; Celcer, L; Hasl, N; Rieper, V; Stadlbauer, V; Horvath, A
Microbial Dysbiosis in the Urinary Microbiome of Patients with Cirrhosis.
Am J Gastroenterol. 2026;
Doi: 10.14309/ajg.0000000000003634
Web of Science
PubMed
FullText
FullText_MUG
2025
Originalarbeit (Zeitschrift)
** Woltsche, J; Pacher-Deutsch, C; Fürst, S; Gulden, L; Schwarzl, J; Feldbacher, N; Nepel, M; Rebol, L; Hasl, N; Rieper, V; Stadlbauer, V; Horvath, A
Distinct Urinary Microbiome Signatures Are Associated with UTI Risk in Patients with Liver Cirrhosis: A Pilot Study.
Int J Infect Dis. 2025; 108031
Doi: 10.1016/j.ijid.2025.108031
Web of Science
PubMed
FullText
FullText_MUG
Abstract (Zeitschrift)
** Horvath, A; Habich, D; Feldbacher, N; Celcer, L; Stadlbauer, V
L-ornithine-L-aspertate improves quality of life and ammonia levels but not microbiome dysbiosis in cirrhosis: results of a phase 4 study
J HEPATOL. 2025; 82: -European-Association-for-the-Study-of-the-Liver Congress; MAY 07-10, 2025; Amsterdam, NETHERLANDS.
[Poster]
Web of Science